Efficacy of iodine solution administered via a treatment applicator for treating human papillomavirus (HPV) infection of the cervix.

Phase 1

• Conditions: Cervical human papillomavirus infection; Infection - Sexually transmitted infections

• Registration Number: ACTRN12617000726358
• Lead Sponsor: Jenny McClloskey

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-05-18
• Last Update Posted: 15 July 2019

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: Female
• Target Recruitment: 60

Inclusion Criteria

Women previously treated for CIN 2 - 3 with persistent HrHPV post treatment.
Women Digene Hybrid Capture 2 positive (or other HPV test)
Women 25 year or over

Exclusion Criteria

Under the age of 25
Male
Pregnancy, or planning to become pregnant
Current thyroid disease
Past history of thyroid disease
Family history of thyroid disease
History of allergy to iodine
History of allergy to rubber
History of anaphylaxis
Untreated gonorrhoea, or chlamydia
Current CIN 2 – 3 on cytology or biopsy
HIV infection or other immune deficiency
Impaired renal function
Autoimmune disorders
Systemic or topical steroid therapy
IUCD in situ

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Proportion of participants with an 80% reduction in human papillomavirus viral load on the uterine cervix. Measurements of viral load will be taken using a cervical lavage and a swab from the cervix.[ 6 weeks post treatment ]

Secondary Outcome Measures

Name	Time	Method
one[None]